Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics presented initial data from its ongoing Phase 1/2 TRESR clinical trial for camonsertib (RP-3500), an ATR inhibitor, in combination with PARPis at the 2023 AACR Annual Meeting. The trials show a 48% clinical benefit rate across various tumor types, especially in late-line ovarian cancer with a 58% clinical benefit rate and a median progression-free survival of about 7 months. Early ctDNA responses indicated a strong antitumor activity, with 66% of evaluable patients responding positively. The treatment showed a favorable safety profile with manageable toxicities. Repare is focused on optimizing doses and expanding studies in different tumor types as part of its collaboration with Roche.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced that data from Phase I/II trials of camonsertib in combination with PARP inhibitors has been selected for presentation at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023. The presentation will highlight safety and efficacy results in patients with solid tumors with DNA damage response alterations, featuring Dr. Timothy Yap. Additionally, two poster presentations will characterize genomic features in ovarian and uterine cancers. Repare's SNIPRx® platform enables the development of precision oncology therapies targeting genomic instability, showcasing its commitment to innovative cancer treatment.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
